ARCHIVES

FDA Should Delay Provenge Decision Pending Definitive Trial Results, ODAC Chairman Writes.

This article is from The Cancer Letter archive.

Vol. 33 No. 16 | April 27, 2007

Download PDF Visit The Full Archive

Related Articles

Award Fees Show House NCI thinks FCRF Contractors Are Performing

August 15, 1986

FPD-R Regimen Well-Tolerated, With 63 Percent Complete Response

July 29, 2011

HCFA Abadons Plan To Cut Cancer Drug Payments.

September 15, 2000

NCI Sends Letter To Grantees To Explain Tighter Funding.

March 16, 2001

Study: Blood Test More Accurate Than Traditional Tumor Biopsy

April 26, 2013

Irinotecan And Carboplatin Improve Response In NSCLC

June 24, 2005